View ValuationRenascience 将来の成長Future 基準チェック /06現在、 Renascienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長8.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Mar 05Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc.On March 5, 2026, Renascience Inc closed the transaction. Stock acquisition right exercise till September 5, 2029.Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.Board Change • Jul 21High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Toshio Miyata is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Jun 03Renascience Inc. to Report Q1, 2026 Results on Aug 13, 2025Renascience Inc. announced that they will report Q1, 2026 results on Aug 13, 2025お知らせ • May 14Renascience Inc., Annual General Meeting, Jun 26, 2025Renascience Inc., Annual General Meeting, Jun 26, 2025.お知らせ • Mar 01Renascience Inc. to Report Fiscal Year 2025 Results on May 14, 2025Renascience Inc. announced that they will report fiscal year 2025 results on May 14, 2025New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (JP¥129m revenue, or US$815k). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥3.84b market cap, or US$24.2m).分析記事 • Jan 01Is Renascience (TSE:4889) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...お知らせ • Dec 03Renascience Inc. to Report Q3, 2025 Results on Feb 13, 2025Renascience Inc. announced that they will report Q3, 2025 results on Feb 13, 2025お知らせ • Aug 28Renascience Inc. to Report Q2, 2025 Results on Nov 14, 2024Renascience Inc. announced that they will report Q2, 2025 results on Nov 14, 2024Reported Earnings • Aug 13First quarter 2025 earnings released: JP¥1.26 loss per share (vs JP¥0.16 profit in 1Q 2024)First quarter 2025 results: JP¥1.26 loss per share (down from JP¥0.16 profit in 1Q 2024). Net loss: JP¥16.0m (down JP¥18.0m from profit in 1Q 2024).New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥194m revenue, or US$1.2m). Market cap is less than US$100m (JP¥4.51b market cap, or US$28.8m).Board Change • Jul 05High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Outside Director Yasunori Nishiyama is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Jun 10Renascience Inc. to Report Q1, 2025 Results on Aug 08, 2024Renascience Inc. announced that they will report Q1, 2025 results on Aug 08, 2024Reported Earnings • May 11Full year 2024 earnings released: JP¥20.30 loss per share (vs JP¥26.35 loss in FY 2023)Full year 2024 results: JP¥20.30 loss per share (improved from JP¥26.35 loss in FY 2023). Revenue: JP¥194.0m (up 94% from FY 2023). Net loss: JP¥258.0m (loss narrowed 23% from FY 2023).お知らせ • May 11Renascience Inc., Annual General Meeting, Jun 27, 2024Renascience Inc., Annual General Meeting, Jun 27, 2024.分析記事 • Apr 05Is Renascience (TSE:4889) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Mar 02Renascience Inc. to Report Fiscal Year 2024 Results on May 09, 2024Renascience Inc. announced that they will report fiscal year 2024 results on May 09, 2024お知らせ • Nov 29Renascience Inc. to Report Q3, 2024 Results on Feb 08, 2024Renascience Inc. announced that they will report Q3, 2024 results on Feb 08, 2024お知らせ • Aug 30Renascience Inc. to Report Q2, 2024 Results on Nov 09, 2023Renascience Inc. announced that they will report Q2, 2024 results on Nov 09, 2023Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.16 (vs JP¥4.96 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.16 (up from JP¥4.96 loss in 1Q 2023). Revenue: JP¥93.0m (up 365% from 1Q 2023). Net income: JP¥2.00m (up JP¥65.0m from 1Q 2023). Profit margin: 2.2% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.お知らせ • Jun 02Renascience Inc. to Report Q1, 2024 Results on Aug 10, 2023Renascience Inc. announced that they will report Q1, 2024 results on Aug 10, 2023お知らせ • May 13Renascience Inc., Annual General Meeting, Jun 29, 2023Renascience Inc., Annual General Meeting, Jun 29, 2023.Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥5.74 loss per share (vs JP¥7.09 loss in 3Q 2022)Third quarter 2023 results: JP¥5.74 loss per share (improved from JP¥7.09 loss in 3Q 2022). Net loss: JP¥73.0m (loss narrowed 19% from 3Q 2022).お知らせ • Nov 27Renascience Inc. to Report Q3, 2023 Results on Feb 09, 2023Renascience Inc. announced that they will report Q3, 2023 results on Feb 09, 2023Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).お知らせ • Aug 28Renascience Inc. to Report Q2, 2023 Results on Nov 10, 2022Renascience Inc. announced that they will report Q2, 2023 results on Nov 10, 2022Reported Earnings • Aug 13First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥4.96 loss per share. Net loss: JP¥63.0m (flat on 1Q 2022).お知らせ • Jun 25Renascience Inc. to Report Q1, 2023 Results on Aug 10, 2022Renascience Inc. announced that they will report Q1, 2023 results on Aug 10, 2022お知らせ • May 14Renascience Inc., Annual General Meeting, Jun 29, 2022Renascience Inc., Annual General Meeting, Jun 29, 2022.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 08Renascience Inc. to Report Fiscal Year 2022 Results on May 12, 2022Renascience Inc. announced that they will report fiscal year 2022 results on May 12, 2022お知らせ • Sep 25Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion.Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,951,400 Price\Range: ¥670 Discount Per Security: ¥53.6 Transaction Features: Sponsor Backed Offering このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Renascience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測TSE:4889 - アナリストの将来予測と過去の財務データ ( )JPY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025107-259N/AN/AN/A9/30/20258734-277-277N/A6/30/202510263N/AN/AN/A3/31/2025132113-176-176N/A12/31/2024139118N/AN/AN/A9/30/2024129-235-279-278N/A6/30/2024141-276N/AN/AN/A3/31/2024194-258-231-230N/A12/31/2023190-331N/AN/AN/A9/30/2023200-277-231-229N/A6/30/2023173-270N/AN/AN/A3/31/2023100-335-286-284N/A12/31/2022103-316N/AN/AN/A9/30/2022128-288-345-344N/A6/30/2022128-285N/AN/AN/A3/31/2022139-254-231-230N/A3/31/2021209-100N/AN/AN/A3/31/202072-184N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 4889の予測収益成長が 貯蓄率 ( 0.8% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 4889の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 4889の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 4889の収益がJP市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 4889の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 4889の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 04:57終値2026/05/11 00:00収益2025/12/31年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Renascience Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Mar 05Renascience Inc. announced that it has received ¥459.972744 million in funding from CVI Investments, Inc.On March 5, 2026, Renascience Inc closed the transaction. Stock acquisition right exercise till September 5, 2029.
Reported Earnings • Feb 16Third quarter 2026 earnings released: JP¥5.25 loss per share (vs JP¥17.78 profit in 3Q 2025)Third quarter 2026 results: JP¥5.25 loss per share (down from JP¥17.78 profit in 3Q 2025). Net loss: JP¥67.0m (down 130% from profit in 3Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Nov 29Renascience Inc. to Report Q3, 2026 Results on Feb 13, 2026Renascience Inc. announced that they will report Q3, 2026 results on Feb 13, 2026
Reported Earnings • Nov 15Second quarter 2026 earnings released: JP¥6.69 loss per share (vs JP¥4.41 loss in 2Q 2025)Second quarter 2026 results: JP¥6.69 loss per share (further deteriorated from JP¥4.41 loss in 2Q 2025). Net loss: JP¥85.0m (loss widened 52% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Sep 01Renascience Inc. to Report Q2, 2026 Results on Nov 12, 2025Renascience Inc. announced that they will report Q2, 2026 results on Nov 12, 2025
Reported Earnings • Aug 15First quarter 2026 earnings released: JP¥5.19 loss per share (vs JP¥1.26 loss in 1Q 2025)First quarter 2026 results: JP¥5.19 loss per share (further deteriorated from JP¥1.26 loss in 1Q 2025). Revenue: JP¥10.0m (down 75% from 1Q 2025). Net loss: JP¥66.0m (loss widened 313% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has increased by 93% per year, which means it is tracking significantly ahead of earnings growth.
Board Change • Jul 21High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. CEO & Chairman Toshio Miyata is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Jun 30Full year 2025 earnings released: EPS: JP¥8.89 (vs JP¥20.30 loss in FY 2024)Full year 2025 results: EPS: JP¥8.89 (up from JP¥20.30 loss in FY 2024). Revenue: JP¥132.0m (down 32% from FY 2024). Net income: JP¥113.0m (up JP¥371.0m from FY 2024). Profit margin: 86% (up from net loss in FY 2024). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has increased by 72% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Jun 03Renascience Inc. to Report Q1, 2026 Results on Aug 13, 2025Renascience Inc. announced that they will report Q1, 2026 results on Aug 13, 2025
お知らせ • May 14Renascience Inc., Annual General Meeting, Jun 26, 2025Renascience Inc., Annual General Meeting, Jun 26, 2025.
お知らせ • Mar 01Renascience Inc. to Report Fiscal Year 2025 Results on May 14, 2025Renascience Inc. announced that they will report fiscal year 2025 results on May 14, 2025
New Risk • Jan 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (JP¥129m revenue, or US$815k). Minor Risks Share price has been volatile over the past 3 months (5.0% average weekly change). Market cap is less than US$100m (JP¥3.84b market cap, or US$24.2m).
分析記事 • Jan 01Is Renascience (TSE:4889) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
お知らせ • Dec 03Renascience Inc. to Report Q3, 2025 Results on Feb 13, 2025Renascience Inc. announced that they will report Q3, 2025 results on Feb 13, 2025
お知らせ • Aug 28Renascience Inc. to Report Q2, 2025 Results on Nov 14, 2024Renascience Inc. announced that they will report Q2, 2025 results on Nov 14, 2024
Reported Earnings • Aug 13First quarter 2025 earnings released: JP¥1.26 loss per share (vs JP¥0.16 profit in 1Q 2024)First quarter 2025 results: JP¥1.26 loss per share (down from JP¥0.16 profit in 1Q 2024). Net loss: JP¥16.0m (down JP¥18.0m from profit in 1Q 2024).
New Risk • Jul 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 15% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.5% average weekly change). Revenue is less than US$5m (JP¥194m revenue, or US$1.2m). Market cap is less than US$100m (JP¥4.51b market cap, or US$28.8m).
Board Change • Jul 05High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Outside Director Yasunori Nishiyama is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Jun 10Renascience Inc. to Report Q1, 2025 Results on Aug 08, 2024Renascience Inc. announced that they will report Q1, 2025 results on Aug 08, 2024
Reported Earnings • May 11Full year 2024 earnings released: JP¥20.30 loss per share (vs JP¥26.35 loss in FY 2023)Full year 2024 results: JP¥20.30 loss per share (improved from JP¥26.35 loss in FY 2023). Revenue: JP¥194.0m (up 94% from FY 2023). Net loss: JP¥258.0m (loss narrowed 23% from FY 2023).
お知らせ • May 11Renascience Inc., Annual General Meeting, Jun 27, 2024Renascience Inc., Annual General Meeting, Jun 27, 2024.
分析記事 • Apr 05Is Renascience (TSE:4889) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Mar 02Renascience Inc. to Report Fiscal Year 2024 Results on May 09, 2024Renascience Inc. announced that they will report fiscal year 2024 results on May 09, 2024
お知らせ • Nov 29Renascience Inc. to Report Q3, 2024 Results on Feb 08, 2024Renascience Inc. announced that they will report Q3, 2024 results on Feb 08, 2024
お知らせ • Aug 30Renascience Inc. to Report Q2, 2024 Results on Nov 09, 2023Renascience Inc. announced that they will report Q2, 2024 results on Nov 09, 2023
Reported Earnings • Aug 13First quarter 2024 earnings released: EPS: JP¥0.16 (vs JP¥4.96 loss in 1Q 2023)First quarter 2024 results: EPS: JP¥0.16 (up from JP¥4.96 loss in 1Q 2023). Revenue: JP¥93.0m (up 365% from 1Q 2023). Net income: JP¥2.00m (up JP¥65.0m from 1Q 2023). Profit margin: 2.2% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue.
お知らせ • Jun 02Renascience Inc. to Report Q1, 2024 Results on Aug 10, 2023Renascience Inc. announced that they will report Q1, 2024 results on Aug 10, 2023
お知らせ • May 13Renascience Inc., Annual General Meeting, Jun 29, 2023Renascience Inc., Annual General Meeting, Jun 29, 2023.
Reported Earnings • Feb 12Third quarter 2023 earnings released: JP¥5.74 loss per share (vs JP¥7.09 loss in 3Q 2022)Third quarter 2023 results: JP¥5.74 loss per share (improved from JP¥7.09 loss in 3Q 2022). Net loss: JP¥73.0m (loss narrowed 19% from 3Q 2022).
お知らせ • Nov 27Renascience Inc. to Report Q3, 2023 Results on Feb 09, 2023Renascience Inc. announced that they will report Q3, 2023 results on Feb 09, 2023
Reported Earnings • Nov 16Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).
Reported Earnings • Nov 13Second quarter 2023 earnings released: JP¥7.08 loss per share (vs JP¥7.09 loss in 2Q 2022)Second quarter 2023 results: JP¥7.08 loss per share (improved from JP¥7.09 loss in 2Q 2022). Net loss: JP¥90.0m (flat on 2Q 2022).
お知らせ • Aug 28Renascience Inc. to Report Q2, 2023 Results on Nov 10, 2022Renascience Inc. announced that they will report Q2, 2023 results on Nov 10, 2022
Reported Earnings • Aug 13First quarter 2023 earnings releasedFirst quarter 2023 results: JP¥4.96 loss per share. Net loss: JP¥63.0m (flat on 1Q 2022).
お知らせ • Jun 25Renascience Inc. to Report Q1, 2023 Results on Aug 10, 2022Renascience Inc. announced that they will report Q1, 2023 results on Aug 10, 2022
お知らせ • May 14Renascience Inc., Annual General Meeting, Jun 29, 2022Renascience Inc., Annual General Meeting, Jun 29, 2022.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 08Renascience Inc. to Report Fiscal Year 2022 Results on May 12, 2022Renascience Inc. announced that they will report fiscal year 2022 results on May 12, 2022
お知らせ • Sep 25Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion.Renascience Inc. has completed an IPO in the amount of ¥1.977438 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 2,951,400 Price\Range: ¥670 Discount Per Security: ¥53.6 Transaction Features: Sponsor Backed Offering